产品说明书

Levofloxacin

Print
Chemical Structure| 100986-85-4 同义名 : (-)-Ofloxacin;MP-376;Levofloxacin, Levaquin, Tavanic, Iquix, Quixin;Fluoroquinolone
CAS号 : 100986-85-4
货号 : A105051
分子式 : C18H20FN3O4
纯度 : 97%
分子量 : 361.368
MDL号 : MFCD00865049
存储条件：

粉末 Inert atmosphere,Room Temperature

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 9 mg/mL(24.91 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 5 mg/mL(13.84 mM)
动物实验配方：
生物活性
靶点

  • Topo II
描述 Levofloxacin is a new fluoroquinolone antibiotic which is the active isomer of ofloxacin[3]. It is active against S. aureus, S. epidermidis, B. subtilis, E. coli, P. aeruginosa, and K. pneumoniae (MICs = 0.25, 0.25, 0.5, 0.03, 4, and 0.25 μg/ml, respectively)[4]. In stable chronic obstructive pulmonary disease, levofloxacin treatment (500mg/day) causes a short term reduction in bacterial load among patients[5].
细胞研究
细胞系 浓度 检测类型 检测时间 活动说明 数据源
HEK293 cells Function assay 1.5 mins Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay, IC50=17.9 μM 23241029
human 5637 cells 200 to 300 ug/ml Function assay 12 h Antibacterial activity against uropathogenic Escherichia coli UTI89 infected in human 5637 cells assessed as decrease in intracellular bacterial level at 200 to 300 ug/ml after 12 hrs by serial dilution method 20231390
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00020865 Fever, Sweats, and Hot Flashes... 展开 >> Infection Leukemia Lymphoma Neutropenia Unspecified Adult Solid Tumor, Protocol Specific 收起 << Phase 3 Unknown - United States, California ... 展开 >> Jonsson Comprehensive Cancer Center, UCLA Los Angeles, California, United States, 90095-1781 收起 <<
NCT01131026 Helicobacter Pylori Infection Phase 3 Completed - Turkey ... 展开 >> Erciyes University School of Medicine Hospital, Department of Internal Medicine and Gastroenterology Kayseri, Turkey, 38039 收起 <<
NCT02975570 Tuberculosis Multi Drug Resist... 展开 >>ant Active 收起 << Phase 3 Withdrawn(The study could not ... 展开 >>be conducted since funding was not obtained.) 收起 << August 2022 -
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.77mL

0.55mL

0.28mL

13.84mL

2.77mL

1.38mL

27.67mL

5.53mL

2.77mL
参考文献

[1]Davis R, Bryson HM. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs. 1994 Apr;47(4):677-700.

[2]Fu KP, Lafredo SC, et al. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Antimicrob Agents Chemother. 1992 Apr;36(4):860-6.

[3]S Ragnar Norrby. Levofloxacin. Expert Opinion on Pharmacotherapy. 1999;1(1): 109-119.

[4]Mohammadhosseini N, Alipanahi Z, Alipour E, et al. Synthesis and antibacterial activity of novel levofloxacin derivatives containing a substituted thienylethyl moiety. Daru. 2012;20(1):16.

[5]Siva R, Bafadhel M, Monteiro W, Brightling CE, Pavord ID. Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial. Int J Chron Obstruct Pulmon Dis. 2014;9:179-186.